Skip to main content
Premium Trial:

Request an Annual Quote

908 Devices Raises Additional $1.4M in Series C Round

NEW YORK (GenomeWeb) – 908 Devices today announced that it has raised an additional $1.4 million as part of a Series C round of financing, bringing the total raised in the round to $13 million.

The latest fundraising included investments from Casdin Capital, as well as Ortho Clinical Diagnostics Chairman and CEO Martin Madaus and former Thermo Fisher Scientific Chairman Paul Meister, among others.

In May, the company said that it raised $11.6 million in a round led by Saudi Aramco Energy Ventures, the corporate venturing subsidiary of Saudi Arabia's national oil company. Also participating were existing investors Arch Venture Partners, Razor's Edge Ventures, University of Tokyo Edge Capital, international oilfield service firm Schlumberger, as well as certain individual investors.

In total, 908 Devices has raised $29 million.

The company said the Series C capital would be used to expand commercialization efforts around its M908 miniature mass spectrometry device, as well as develop the product for new applications in the oil and gas, environmental, and life science markets.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.